Differentiation of Metastatic Vs Degenerative Joint Disease Using Semi-quantitative Analysis with (18)F-NaF PET/CT in Castrate Resistant Prostate Cancer Patients

Overview

Journal Am J Nucl Med Mol Imaging

Date 2015 May 15

PMID 25973337

Citations 12

Authors

Saima Muzahir

Robert Jeraj

Glenn Liu

Lance T Hall

Alejandro Munoz Del Rio

Timothy Perk

Christine Jaskowiak

Scott B Perlman

Affiliations

Soon will be listed here.

Abstract

Fluorine 18 Sodium Fluoride ((18)F-NaF) (sodium fluoride) PET/CT is a highly sensitive but is a non-specific method for identifying bone metastases. Qualitative scan interpretation using low dose CT for lesion localization is often complicated by the presence of co-existing degenerative joint disease (DJD). A semi-quantitative analysis might help in accurately differentiating benign from metastatic osseous lesions. The aim of the study was to evaluate the clinical utility of (18)F-NaF PET/CT in differentiating DJD from metastatic disease in the skeleton using a qualitative analysis as well as a semi-quantitative approach using the SUVmax and to determine if there is an upper limit of SUVmax value that can reliably differentiate metastases from DJD. Baseline (18)F-NaF PET/CT scans were performed for 17 castrate resistant prostate cancer patients (CRPC). A qualitative as well as semi-quantitative analysis using maximum standardized uptake value (SUVmax) based on body weight was performed for 65 metastatic and 56 DJD sites identified on the low dose CT scan acquired as a part of whole body PET/CT scan. The SUVmax range in DJD was 2.6-49.9 (mean: 6.2). The SUVmax range for metastatic lesions was 11.2-188 (mean: 160). The SUVmax value for metastatic as well as areas of DJD showed significant variation during treatment. Bone metastases showed statistically significantly higher SUVmax than DJD using a mixed effect regression model. ROC/AUC analysis was performed based on averaging the SUVs over all lesions in each subject. The AUC was found to be fairly high at 0.964 (95% CI: 0.75-0.996). The SUVmax over 50 always represented a bone metastasis and below 12 always represented a site of DJD. The results of our preliminary data show that semi-quantitative analysis is complementary to the qualitative analysis in accurately identifying DJD from metastatic disease. The cut-off SUVmax of 50 can help in differentiating DJD from bone metastases.

Citing Articles

Correlation between the maximum standard uptake value and mean Hounsfield unit on single-photon emission computed tomography-computed tomography to discriminate benign and metastatic lesions among patients with breast cancer.

Saminathan S, Wan Ahmed W, Nawi N, Tagiling N, Aziz I, Udin Y Asian Spine J. 2024; 18(3):398-406.

PMID: 38917860 PMC: 11222895. DOI: 10.31616/asj.2022.0451.

Ga-P15-041, A Novel Bone Imaging Agent for Diagnosis of Bone Metastases.

Guo R, Meng X, Wang F, Yu J, Xie Q, Zhao W Front Oncol. 2021; 11:766851.

PMID: 34900716 PMC: 8654731. DOI: 10.3389/fonc.2021.766851.

Clinical value of dual-phase F-18 sodium fluoride PET/CT for diagnosing bone metastasis in cancer patients with solitary bone lesion.

Lee J, Park Y, Jeon Y, Kim K, Lee J, Hong S Quant Imaging Med Surg. 2020; 10(11):2098-2111.

PMID: 33139990 PMC: 7547267. DOI: 10.21037/qims-20-607.

Standardized Uptake Value from Semiquantitative Bone Single-Photon Emission Computed Tomography/Computed Tomography in Normal Thoracic and Lumbar Vertebrae of Breast Cancer Patients.

Mohd Rohani M, Yonan S, Tagiling N, Wan Zainon W, Udin Y, Nawi N Asian Spine J. 2020; 14(5):629-638.

PMID: 32213791 PMC: 7595810. DOI: 10.31616/asj.2019.0308.

Targeted α-therapy of prostate cancer using radiolabeled PSMA inhibitors: a game changer in nuclear medicine.

Chakravarty R, Siamof C, Dash A, Cai W Am J Nucl Med Mol Imaging. 2018; 8(4):247-267.

PMID: 30245917 PMC: 6146164.

References

Schiepers C, Nuyts J, Bormans G, Dequeker J, Bouillon R, Mortelmans L . Fluoride kinetics of the axial skeleton measured in vivo with fluorine-18-fluoride PET. J Nucl Med. 1998; 38(12):1970-6. View

Cook G, Fogelman I . The role of positron emission tomography in the management of bone metastases. Cancer. 2000; 88(12 Suppl):2927-33. DOI: 10.1002/1097-0142(20000615)88:12+<2927::aid-cncr8>3.3.co;2-m. View

Rosen R, Fayad L, Wahl R . Increased 18F-FDG uptake in degenerative disease of the spine: Characterization with 18F-FDG PET/CT. J Nucl Med. 2006; 47(8):1274-80. View

Al-Beyatti Y, Siddique M, Frost M, Fogelman I, Blake G . Precision of ¹⁸F-fluoride PET skeletal kinetic studies in the assessment of bone metabolism. Osteoporos Int. 2012; 23(10):2535-41. DOI: 10.1007/s00198-011-1889-2. View

Rybak L, Rosenthal D . Radiological imaging for the diagnosis of bone metastases. Q J Nucl Med. 2001; 45(1):53-64. View

Blake G, Park-Holohan S, Cook G, Fogelman I . Quantitative studies of bone with the use of 18F-fluoride and 99mTc-methylene diphosphonate. Semin Nucl Med. 2001; 31(1):28-49. DOI: 10.1053/snuc.2001.18742. View

Hamaoka T, Madewell J, Podoloff D, Hortobagyi G, Ueno N . Bone imaging in metastatic breast cancer. J Clin Oncol. 2004; 22(14):2942-53. DOI: 10.1200/JCO.2004.08.181. View

Schirrmeister H, Glatting G, Hetzel J, Nussle K, Arslandemir C, Buck A . Prospective evaluation of the clinical value of planar bone scans, SPECT, and (18)F-labeled NaF PET in newly diagnosed lung cancer. J Nucl Med. 2001; 42(12):1800-4. View

Hawkins R, Choi Y, Huang S, Hoh C, Dahlbom M, Schiepers C . Evaluation of the skeletal kinetics of fluorine-18-fluoride ion with PET. J Nucl Med. 1992; 33(5):633-42. View

10.

Aoki J, Watanabe H, Shinozaki T, Takagishi K, Ishijima H, Oya N . FDG PET of primary benign and malignant bone tumors: standardized uptake value in 52 lesions. Radiology. 2001; 219(3):774-7. DOI: 10.1148/radiology.219.3.r01ma08774. View

11.

Li Y, Schiepers C, Lake R, Dadparvar S, Berenji G . Clinical utility of (18)F-fluoride PET/CT in benign and malignant bone diseases. Bone. 2011; 50(1):128-39. DOI: 10.1016/j.bone.2011.09.053. View

12.

Blau M, Nagler W, Bender M . Fluorine-18: a new isotope for bone scanning. J Nucl Med. 1962; 3:332-4. View

13.

Even-Sapir E, Metser U, Mishani E, Lievshitz G, Lerman H, Leibovitch I . The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. J Nucl Med. 2006; 47(2):287-97. View

14.

Even-Sapir E . Imaging of malignant bone involvement by morphologic, scintigraphic, and hybrid modalities. J Nucl Med. 2005; 46(8):1356-67. View

15.

Schirrmeister H, Guhlmann A, Elsner K, Kotzerke J, Glatting G, Rentschler M . Sensitivity in detecting osseous lesions depends on anatomic localization: planar bone scintigraphy versus 18F PET. J Nucl Med. 1999; 40(10):1623-9. View

16.

Cook Jr G, Parker C, Chua S, Johnson B, Aksnes A, Lewington V . 18F-fluoride PET: changes in uptake as a method to assess response in bone metastases from castrate-resistant prostate cancer patients treated with 223Ra-chloride (Alpharadin). EJNMMI Res. 2012; 1(1):4. PMC: 3192465. DOI: 10.1186/2191-219X-1-4. View

17.

Schirrmeister H, Guhlmann A, Kotzerke J, Santjohanser C, Kuhn T, Kreienberg R . Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography. J Clin Oncol. 1999; 17(8):2381-9. DOI: 10.1200/JCO.1999.17.8.2381. View

18.

Keyes Jr J . SUV: standard uptake or silly useless value?. J Nucl Med. 1995; 36(10):1836-9. View

19.

Georgy B . Metastatic spinal lesions: state-of-the-art treatment options and future trends. AJNR Am J Neuroradiol. 2008; 29(9):1605-11. PMC: 8118803. DOI: 10.3174/ajnr.A1137. View

20.

Tryciecky E, Gottschalk A, Ludema K . Oncologic imaging: interactions of nuclear medicine with CT and MRI using the bone scan as a model. Semin Nucl Med. 1997; 27(2):142-51. DOI: 10.1016/s0001-2998(97)80044-x. View